Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1TED8
|
|||
| Drug Name |
Reloxaliase
|
|||
| Synonyms |
ALLN-177
Click to Show/Hide
|
|||
| Drug Type |
Protein
|
|||
| Indication | Hyperoxaluria [ICD-11: 5C51.2] | Phase 3 | [1] | |
| Company |
Allena Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxalate absorption (Oxalate absor) | Target Info | Replacement | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03847090) Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria (URIROX-2). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Allena Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.